Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

03 Mar 2010
Director/PDMR Shareholding

March 3, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company announces the release on March 2, 2010 of Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) in Shire plc in connection with Performance Share Awards (“PSP Awards”) granted in 2007 under Part B of the Shire Portfolio Share Plan (the “Plan”) to Persons Discharging Managerial Responsibility (“PDMR”).

In accordance with the rules of the Plan, the following Shares/ADSs were released:

Name of PDMRType of SecurityNo of Shares/ADSs released No of Shares/ADSs sold to satisfy tax liabilities
Matthew Emmens (Director)ADSs 60,066 26,764
Angus Russell (Director)Shares 68,27727,038
Tatjana May Shares 30,480 12,448
Anita Graham ADSs8,4673,334
Barbara Deptula ADSs 10,160 4,397
Michael ColaADSs 14,224 5,600

The PSP Awards for Matthew Emmens and Angus Russell were subject to performance criteria measured over the performance period 2007 to 2009.  Based on the performance criteria, 84% of the PSP Awards vested.

All PDMRs sold sufficient Shares/ADSs, on March 2, 2010, at prices of £14.487 and $65.293 respectively, to satisfy tax liabilities as set out above. 

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary

For further information please contact:

Investor RelationsCléa Rosenfeld (Rest of the World)  +44 1256 894 160
 Eric Rojas (North America) +1 617 551 9715

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

« Back to Shire news

Did you know...

You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.

Email and SMS alerts

Did you know...

We donated over $35,000 in
outdated laboratory
equipment
to local
schools?